BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 30209679)

  • 1. Roles of intestinal microbiota in response to cancer immunotherapy.
    Cong J; Zhang X
    Eur J Clin Microbiol Infect Dis; 2018 Dec; 37(12):2235-2240. PubMed ID: 30209679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint Inhibitors: Conquering Cancer with a Little (T)-Help from Our Microbial Friends.
    Asmar N; Ibrahim T; Rey JF
    Dig Dis Sci; 2018 Sep; 63(9):2177-2179. PubMed ID: 29982987
    [No Abstract]   [Full Text] [Related]  

  • 3. New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era.
    Innao V; Allegra AG; Musolino C; Allegra A
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intimate relationship between gut microbiota and cancer immunotherapy.
    Elkrief A; Derosa L; Zitvogel L; Kroemer G; Routy B
    Gut Microbes; 2019; 10(3):424-428. PubMed ID: 30339501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer.
    Kim E; Ahn H; Park H
    Mamm Genome; 2021 Aug; 32(4):223-231. PubMed ID: 33783613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.
    Champiat S; Lambotte O; Barreau E; Belkhir R; Berdelou A; Carbonnel F; Cauquil C; Chanson P; Collins M; Durrbach A; Ederhy S; Feuillet S; François H; Lazarovici J; Le Pavec J; De Martin E; Mateus C; Michot JM; Samuel D; Soria JC; Robert C; Eggermont A; Marabelle A
    Ann Oncol; 2016 Apr; 27(4):559-74. PubMed ID: 26715621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut Microbiota in Cancer Immune Response and Immunotherapy.
    Zhou CB; Zhou YL; Fang JY
    Trends Cancer; 2021 Jul; 7(7):647-660. PubMed ID: 33674230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immune-related adverse events of immune checkpoint inhibitors].
    Tadano H; Torigoe T
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):102-108. PubMed ID: 28603200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gut microbiota and immune checkpoint inhibitors.
    Humphries A; Daud A
    Hum Vaccin Immunother; 2018; 14(9):2178-2182. PubMed ID: 29494275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.
    Yi M; Jiao D; Qin S; Chu Q; Li A; Wu K
    Integr Cancer Ther; 2019; 18():1534735419876351. PubMed ID: 31517538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.
    Wang Y; Wiesnoski DH; Helmink BA; Gopalakrishnan V; Choi K; DuPont HL; Jiang ZD; Abu-Sbeih H; Sanchez CA; Chang CC; Parra ER; Francisco-Cruz A; Raju GS; Stroehlein JR; Campbell MT; Gao J; Subudhi SK; Maru DM; Blando JM; Lazar AJ; Allison JP; Sharma P; Tetzlaff MT; Wargo JA; Jenq RR
    Nat Med; 2018 Dec; 24(12):1804-1808. PubMed ID: 30420754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
    Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
    Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.
    Matson V; Chervin CS; Gajewski TF
    Gastroenterology; 2021 Jan; 160(2):600-613. PubMed ID: 33253684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
    Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
    Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Gut Microbiota in Tumor Immunotherapy.
    Wu M; Bai J; Ma C; Wei J; Du X
    J Immunol Res; 2021; 2021():5061570. PubMed ID: 34485534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal microbiota and colorectal cancer: a new aspect of research.
    Koliarakis I; Psaroulaki A; Nikolouzakis TK; Kokkinakis M; Sgantzos MN; Goulielmos G; Androutsopoulos VP; Tsatsakis A; Tsiaoussis J
    J BUON; 2018; 23(5):1216-1234. PubMed ID: 30512251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbial biomarkers for immune checkpoint blockade therapy against cancer.
    Adachi K; Tamada K
    J Gastroenterol; 2018 Sep; 53(9):999-1005. PubMed ID: 30003334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.